Allergic Asthma Clinical Trial
Official title:
Eosinophil Induced Airway Smooth Muscle Remodelling in Asthma
Asthma is a chronic, inflammatory disease of the lung characterized by intermittent airway
obstruction, airway hyperresponsiveness, presence of activated inflammatory cells,
inflammatory mediators, and airway structural changes. Airway smooth muscle (ASM) cells
actively participate in the remodelling and inflammatory processes through proliferation,
release of proinflammatory cytokines, chemokines, and extracellular matrix (ECM) proteins.
Eosinophils as essential inflammatory cells may be of importance in ASM remodelling. It is
known that eosinophil induces ASM cells proliferation via the secretion of cysteinyl
leukotrienes in asthmatics. However there is a possible direct eosinophil-ASM cells
functional interaction by adhesion processes. It has been shown that integrins modulate ASM
proliferation and contractile protein expression demonstrating allergen-induced ASM
remodelling in an animal model of allergic asthma.
Wingless/integrase-1 (WNT) signaling regulates not only a wide range of developmental
processes, but its aberrant activation can lead to disease. Recently, it was confirmed that
genes polymorphisms in the WNT signaling pathway are associated with impaired lung function
in childhood asthma. It was also found for the first time a relevant role of noncanonical WNT
signaling in TGFβ-induced ECM expression by ASM cells and identified WNT-5A is the most
abundant WNT ligand with increased expression in asthmatics. It demonstrates that WNT-5A
could contribute to remodelling of the airways. Unfortunately, the effect of eosinophil on
WNT secretion by ASM cells at present is unknown.
Despite the widely acknowledged significance of eosinophils in asthma pathogenesis, the
mechanism of eosinophil induced ASM remodelling is unsolved.
Asthma is a chronic, inflammatory disease of the lung characterized by intermittent airway
obstruction, airway hyperresponsiveness, presence of activated inflammatory cells,
inflammatory mediators, and remodeling in the airway. Airway remodeling characterizes as the
cellular and structural changes in the airways, mainly resulting from repair processes in
response to persistent inflammation. It is generally accepted that airway remodeling is
closely related to the progression of airway hyperresponsiveness and the severity of asthma.
The structural changes in the airway include airway smooth muscle (ASM) hypertrophy and
hyperplasia, collagen deposition to the sub-epithelial basement membrane, hyperplasia of
goblet cells, thickening of the airway mucosa and an increase in vascularity (Aceves and
Broide, 2008).
Airway remodelling mostly is derived from airway inflammation, where eosinophils play a key
role. The effect of intact eosinophils on ASM cells within a physiological context first time
was investigated by Halwani with colleagues (2013). They found that prevention contact of
eosinophils with ASM cells using specific antibodies or blocking cysteinyl leukotrienes was
associated with inhibition of ASM proliferation in asthmatics. Moreover, Fanat et al. (2009)
demonstrated that ASM-derived cytokines directly affect the eosinophils differentiation and
maturation from progenitor cells, which can maintain airway eosinophilic inflammation and
consequently the tissue remodelling in asthma. Furthermore, eosinophil deficient mice are
protected from airway remodeling including collagen deposition and smooth muscle thickening
(Humbles et al Science 2004, 305:1776-9).
Eosinophils seem to contribute to airway remodelling in several ways, including through
release of eosinophil-derived mediators such as transforming growth factor (TGF)-β, secretion
of cationic proteins, and cytokines, as well as through interactions with inflammatory and
structural cells (Kariyawasam and Robinson, 2007; Aceves and Broide, 2008; Venge, 2010).
Eosinophil-derived cytokines are in the modulation of Th2 responses that trigger macrophage
production of TGF-β1, which serves as a stimulus for extracellular matrix (ECM) production
(Fanta et al., 1999; Holgate, 2001). Masu et al. (2002) confirmed the proliferative effects
of eosinophils lysates isolated from healthy donors on ASM cells. However, there is a
possible direct eosinophil-ASM cells functional interaction by adhesion processes.
Interaction of cells is mediated through integrins, a group of heterodimeric transmembrane
glycoproteins (Hynes, 2002). Each integrin interacts or potentially interacts with
counter-receptors on other cells or ligands deposited as part of the ECM (Humphries et al.,
2006). The communication between eosinophil and ASM cells is not fully understood. Several
integrins are expressed by eosinophils (α4β1, α6β1, αLβ2, αMβ2, αXβ2, αDβ2, α4β7) and ASM
cell (α1β1, α2β1, α3β1, α4β1, α5β1, α6β1, α6β4, α7β1, α8β1, α9β1, αvβ1, αvβ3, αvβ5) (Teoh at
al., 2012; Johansson and Mosher, 2013). It has been shown that integrins modulate ASM
proliferation and contractile protein expression demonstrating allergen-induced ASM
remodeling in an animal model of allergic asthma (Bart et al., 2010). Furthermore, several
ASM derived integrins can function to activate latent TGF-beta into active TGF-beta in
asthmatic airway smooth muscle (Tatler et al J Immunol 2011, 187:6094-107). Eosinophil
integrins have the potential to mediate adhesion to endothelium in asthma (Barthel et al.,
2008). Further studies indicate that integrins mediate trafficking of eosinophils to the lung
and persistence in the ECM of the bronchi in models of allergen-induced acute and chronic
asthma (Banerjee et al., 2007, 2009).
Wingless/integrase-1 (WNT) signalling regulates not only a wide range of developmental
processes, but its aberrant activation can lead to disease. Up-regulation of several members
of the WNT signalling pathway in the lungs of patients with idiopathic pulmonary fibrosis and
other interstitial lung diseases has been demonstrated (Selman et al., 2006; Königshoff et
al., 2008). More recently, Sharma et al. (2010) have confirmed that genes polymorphisms in
the WNT signalling pathway are associated with impaired lung function in childhood asthma.
Kumawat et al. (2013) for the first time reported a relevant role of noncanonical WNT
signalling in TGFβ-induced extracellular matrix (ECM) expression by ASM cells and identified
WNT-5A is the most abundant WNT ligand in ASM cells with increased expression in asthmatics.
This is in line with Choy et al. (2011) who report that airway biopsies from Th2 high asthma
patients have increased WNT-5A expression. Higher expression of WNT-5A in ASM cells
demonstrates that WNT-5A could contribute to remodelling of the airways. Despite the reported
role of WNT in airway remodelling, the regulation of WNT secretion by eosinophils or by
eosinophil-ASM interactions is at present unknown.
Despite the widely acknowledged significance of eosinophils in asthma pathogenesis, the
mechanism for eosinophil mediated airway remodeling is unsolved. At present understanding of
eosinophils interaction and effect on ASM cells in asthma remains elusive. Therefore the
nature of the interplay between these two cells types and the consequence of it needs to be
investigated.
The aim of the Project: to assess the eosinophil mediated airway remodeling in asthma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Completed |
NCT02911688 -
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
|
Phase 2 | |
Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
Completed |
NCT00999466 -
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
|
Phase 2 | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|